NZ firm to test pig cells to treat Parkinson's

2012-04-17 09:17
Melbourne - A New Zealand company plans to implant pig cells in the human brain in a clinical trial to treat Parkinson's disease and help improve movement and brain functions in patients.

The clinical trials, planned for next year, would be the first using pig brain cells for potential treatment in humans.

Living Cell Technologies Ltd said on Tuesday the treatment involves transplanting "support" cells from the brain of pigs that can help repair damaged nerve tissue in people with Parkinson's.

Parkinson's is a degenerative disorder of the nervous system that affects four to six million people worldwide. In Parkinson's, reduced dopamine levels in the brain lead to movement-related symptoms such as tremor, rigidity and slow movement, and later cognitive symptoms.

Living Cell Chief Executive Andrea Grant said pre-clinical trials in monkeys showed improvements of greater than 50% in symptoms.

"Within two weeks of implanting the cells, we saw an improvement in the movement tremors that the monkeys had. We saw an improvement in tests of their memory and attention, and the improvement was sustained for the six-month period of the trial," Grant told Reuters.

The results suggested the cell implants could protect brain tissue that would otherwise die, potentially delaying or even preventing the debilitating effects of Parkinson's, Grant said.

Conventional drugs to treat Parkinson's alleviate its symptoms, but they lose effectiveness over time and do not address the underlying loss of the brain cells that produce dopamine.

Modern pigs

"The support cells are like the regeneration engine of the brain. They enable neurons that are sick to regenerate and repopulate the area of the brain that's damaged," Grant said in a telephone interview.

The cells are taken from the brain tissue of newborn pigs from a special "clean" herd, because of the risks of diseases from modern pigs.

The company uses pigs descended from a herd that was left isolated in the 1850s on an abandoned whaling station in the Auckland Islands, some 465km  south of New Zealand.

The cells are treated to prevent the human immune system from rejecting them.

Living Cell Technologies plans to apply to New Zealand authorities in early May and, if approval is granted, to start Phase I trials by the end of the March quarter 2013.

Read more on:    new zealand  |  health  |  science

Join the conversation! encourages commentary submitted via MyNews24. Contributions of 200 words or more will be considered for publication.

We reserve editorial discretion to decide what will be published.
Read our comments policy for guidelines on contributions.

linking and moving

2015-04-22 07:36 publishes all comments posted on articles provided that they adhere to our Comments Policy. Should you wish to report a comment for editorial review, please do so by clicking the 'Report Comment' button to the right of each comment.

Comment on this story
Comments have been closed for this article.

Inside News24


Book flights

Compare, Book, Fly

Traffic Alerts
There are new stories on the homepage. Click here to see them.


Create Profile

Creating your profile will enable you to submit photos and stories to get published on News24.

Please provide a username for your profile page:

This username must be unique, cannot be edited and will be used in the URL to your profile page across the entire network.


Location Settings

News24 allows you to edit the display of certain components based on a location. If you wish to personalise the page based on your preferences, please select a location for each component and click "Submit" in order for the changes to take affect.

Facebook Sign-In

Hi News addict,

Join the News24 Community to be involved in breaking the news.

Log in with Facebook to comment and personalise news, weather and listings.